Article
AVEO Oncology and Astellas Pharma Inc. have announced that the FDA has accepted for filing the new drug application (NDA) for tivozanib with the proposed indication for the treatment of patients with advanced renal cell carcinoma.
PEACE-3 data for radium-223/enzalutamide published in Annals of Oncology
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
ORIC-944 shows promise in combination with AR inhibitors in mCRPC
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
FDA awards Regenerative Medicine Advanced Therapy Designation to CAN-2409 for prostate cancer
Intraprostatic drug elution therapy shows promise for BPH-related LUTS
Phase 2 trial launches of combination immunotherapy for mCRPC
Study findings highlight gender gaps in oncology authorship and citation